Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM: Diclofenac Potassium vs Rimegepant for Acute Migraine Treatment
2021-001057-31Phase 4Active
- Sponsor
- Rigshospitalet Glostrup
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in migraine comparing Diclofenac potassium 50 mg with Rimegepant 75 mg (2 arms). Primary endpoint: Pain freedom at 2 hours. Started Mar 2021; status: active.
02
Drugs
diclofenacrimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2021-001057-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001057-31.